JP6777794B1 - Composition for promoting collagen production - Google Patents

Composition for promoting collagen production Download PDF

Info

Publication number
JP6777794B1
JP6777794B1 JP2019125060A JP2019125060A JP6777794B1 JP 6777794 B1 JP6777794 B1 JP 6777794B1 JP 2019125060 A JP2019125060 A JP 2019125060A JP 2019125060 A JP2019125060 A JP 2019125060A JP 6777794 B1 JP6777794 B1 JP 6777794B1
Authority
JP
Japan
Prior art keywords
collagen
rose
extract
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019125060A
Other languages
Japanese (ja)
Other versions
JP2021011439A (en
Inventor
実保 井野
実保 井野
理恵 今井
理恵 今井
裕実春 武藤
裕実春 武藤
櫻田 剛史
剛史 櫻田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fancl Corp
Original Assignee
Fancl Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fancl Corp filed Critical Fancl Corp
Priority to JP2019125060A priority Critical patent/JP6777794B1/en
Priority to CN202010619260.2A priority patent/CN112167634B/en
Priority to TW109122398A priority patent/TWI855104B/en
Application granted granted Critical
Publication of JP6777794B1 publication Critical patent/JP6777794B1/en
Publication of JP2021011439A publication Critical patent/JP2021011439A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738Rosa (rose)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

【課題】コラーゲン産生促進用組成物を提供すること。【解決手段】バラ科バラ属の植物の花弁及び/又はつぼみのエキスと、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドを有効成分として含有するコラーゲン産生促進用組成物。【選択図】図1PROBLEM TO BE SOLVED: To provide a composition for promoting collagen production. SOLUTION: For promoting collagen production containing an extract of petals and / or buds of a plant belonging to the genus Rosa in the family Rosaceae and two types of tripeptides having sequences of Gly-Pro-Hyp and Gly-Pro-Ala as active ingredients. Composition. [Selection diagram] Fig. 1

Description

本発明は、生体のコラーゲン産生を促進するための新規な組成物に関する。 The present invention relates to a novel composition for promoting collagen production in a living body.

コラーゲンは線維芽細胞から細胞外に分泌されるタンパク質である。コラーゲンは、生体における種々の結合組織に、力学的な強度を与えるのに役立っており、腱の主成分はコラーゲン繊維がきちんとすきまなく配列したもので、非常に強い力に耐える。また、皮膚においては、真皮の乾燥重量のうち約70%をコラーゲンが占めているといわれ、皮膚の弾力性や柔軟性を維持するのに重要な役割を果たしている。また、コラーゲンがそれに接する細胞に対して、増殖、分化シグナルを与えるための情報伝達の働きも担っていることがわかってきている。コラーゲンには種々のタイプが存在することが知られており、30種以上のタイプが報告されている。中でもコラーゲンの線維性を構成する基本のタイプがI型コラーゲンであり、生体の主要構成成分である。脊椎動物では85%〜90%と最も大量に存在するコラーゲンであり、骨に大量に含まれ、骨に弾力性を持たせる働きをしている。また皮膚の真皮にも非常に多く、I型コラーゲンの太い線維によって皮膚の強さを生み出す働きがある。
近年、皮膚の弾力性や、シワの改善を目的としてコラーゲンやコラーゲンの加水分解物を経口摂取することが行われており、「美容ドリンク」や「美肌飲料」などの名称でコラーゲンやコラーゲンの加水分解物を含む飲料が市販されている。これらの飲料は、1回あたりコラーゲン換算で900〜10000mgを摂取することが効果的であるといわれている。
経口摂取したコラーゲンやコラーゲンペプチドがどのような作用機序で皮膚の弾力性やシワの改善に働くのか、詳細な機構は明らかになっていないが、一部のコラーゲンペプチドが、コラーゲンを経口摂取すると血液中に出現することが知られている。そしてそのコラーゲンペプチドが線維芽細胞のI型コラーゲンの産生を促進することも知られている。
Collagen is a protein secreted extracellularly from fibroblasts. Collagen helps to give mechanical strength to various connective tissues in the living body, and the main component of the tendon is a neat arrangement of collagen fibers, which withstands a very strong force. In the skin, collagen is said to account for about 70% of the dry weight of the dermis, and plays an important role in maintaining the elasticity and flexibility of the skin. In addition, it is becoming clear that collagen also plays a role in transmitting information to give proliferation and differentiation signals to cells in contact with it. It is known that there are various types of collagen, and more than 30 types have been reported. Among them, the basic type that constitutes the fibrosis of collagen is type I collagen, which is a major constituent of the living body. Collagen, which is the most abundant in vertebrates at 85% to 90%, is contained in a large amount in bones and functions to make bones elastic. It is also very abundant in the dermis of the skin, and has the function of producing the strength of the skin by the thick fibers of type I collagen.
In recent years, collagen and collagen hydrolysates have been orally ingested for the purpose of improving skin elasticity and wrinkles, and collagen and collagen hydrolyzate under the names such as "beauty drink" and "skin-beautifying drink". Beverages containing decomposition products are commercially available. It is said that it is effective to ingest 900 to 10,000 mg of these beverages in terms of collagen at one time.
The detailed mechanism of the mechanism of action of orally ingested collagen and collagen peptide to improve skin elasticity and wrinkles has not been clarified, but some collagen peptides are used when collagen is ingested orally. It is known to appear in blood. It is also known that the collagen peptide promotes the production of type I collagen in fibroblasts.

特許文献1には、コラーゲンをコラゲナーゼで酵素分解した際に得られるGly−Pro−Hypの構造を有するトリペプチド(コラーゲントリペプチド)が生体コラーゲン合成促進作用を有し、これを含むコラーゲン加水分解物をコラーゲン合成促進剤として利用する技術が記載されている。
特許文献2には、前記のコラーゲントリペプチドとフラボノイドの一種であるシリマリンとリンゴ抽出物が、コラーゲンと線維芽細胞を含むコラーゲンゲルを収縮させ、シワ改善に用いることができることが記載されている。
特許文献3には、Gly−Pro−Hyp、Gly−His−Lys、Lys−Thr−Thr−Lys−Ser、またはGly−Glu−Pro−Argの構造を有するコラーゲン由来のペプチドがシリビンと相乗的にI型コラーゲンの産生を促進することが記載されている。
特許文献4では、コラーゲンを経口摂取した直後に血液中に出現する複数のトリペプチド又はジペプチドを合成して、Ala−Hyp−Gly、Pro−Hyp−Gly、Pro−Hyp、Leu−Hyp、Ala−Hypのジペプチドまたはトリペプチドが培養マウス線維芽細胞に対してコラーゲン合成を促進することを確認して、その結果に基づき、皮膚コラーゲン産生促進剤として利用することを提案している。
特許文献5にはGly−Pro、Pro−Gly、Pro−Hyp、Hyp−Gly、Gly−Hypのいずれかの配列を有するジペプチドを有効成分とするコラーゲン産生促進剤が記載されている。
このように、これまでの研究開発から、コラーゲンタンパク質の加水分解物やコラーゲンペプチド、アミノ酸など多くの物質がコラーゲン産生促進作用を有することが明らかとなっており、引き続き有用な物質の探索が行われている。
In Patent Document 1, a tripeptide (collagen tripeptide) having a Gly-Pro-Hyp structure obtained when collagen is enzymatically decomposed with collagenase has a biological collagen synthesis promoting action, and a collagen hydrolyzate containing the same. Is described as a technique for utilizing as a collagen synthesis promoter.
Patent Document 2 describes that the above-mentioned collagen tripeptide and silymarin and apple extract, which are one of flavonoids, can be used for improving wrinkles by contracting a collagen gel containing collagen and fibroblasts.
In Patent Document 3, a collagen-derived peptide having a structure of Gly-Pro-Hyp, Gly-His-Lys, Lys-Thr-Thr-Lys-Ser, or Gly-Glu-Pro-Arg synergistically with silybin. It has been described to promote the production of type I collagen.
In Patent Document 4, a plurality of tripeptides or dipeptides appearing in blood immediately after oral ingestion of collagen are synthesized to synthesize Ala-Hyp-Gly, Pro-Hyp-Gly, Pro-Hyp, Leu-Hyp, Ala-. It has been confirmed that a Hyp dipeptide or tripeptide promotes collagen synthesis in cultured mouse fibroblasts, and based on the results, it is proposed to use it as a skin collagen production promoter.
Patent Document 5 describes a collagen production promoter containing a dipeptide having a sequence of any one of Gly-Pro, Pro-Gly, Pro-Hyp, Hyp-Gly, and Gly-Hyp as an active ingredient.
As described above, from the research and development so far, it has been clarified that many substances such as collagen protein hydrolyzate, collagen peptide, and amino acid have a collagen production promoting action, and the search for useful substances is continued. ing.

一方、バラ科バラ属の植物の花弁又はつぼみのエキスに様々な作用が見いだされている。そして、これを化粧品や健康食品に配合できることも知られている。特許文献6には、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる少なくとも1種のバラ科バラ属の植物のつぼみ又は花弁を水、親水性有機溶媒又はこれらの混合液により抽出処理して得られた抽出物を有効成分とする抗菌作用組成物や飲食品が記載されている。
特許文献7には、特許文献6と同様の抽出物であって、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる少なくとも1種のバラ科植物のつぼみ又は花弁を水、親水性有機溶媒又はこれらの混合液により抽出処理して得られた抽出物が記載されている。そして、この抽出物に抗インフルエンザウィルス作用を見いだし、これを有効成分とする抗インフルエンザウィルス剤及びこれを配合した飲食品の発明が記載されている。
On the other hand, various actions have been found in the extracts of petals or buds of plants belonging to the genus Rosa in the family Rosaceae. It is also known that this can be incorporated into cosmetics and health foods. Patent Document 6 describes the buds or petals of at least one Rosaceae plant of the Rosaceae genus selected from dog rose, apotecary rose, sweet-brier, damask rose, rose and rose, water, hydrophilic organic solvent or these. The antibacterial action composition and food and drink containing the extract obtained by the extraction treatment with the mixed solution of the above as an active ingredient are described.
Patent Document 7 is an extract similar to Patent Document 6, and is a bud or petal of at least one Rosaceae plant selected from dog rose, apotecary rose, sweet briar, damask rose, rose rose and hamanashi. Is described as an extract obtained by extracting the mixture with water, a hydrophilic organic solvent or a mixture thereof. Then, an anti-influenza virus action is found in this extract, and an invention of an anti-influenza virus agent containing the same as an active ingredient and a food or drink containing the same is described.

特許第3802721号公報Japanese Patent No. 38027221 特許第5572406号公報Japanese Patent No. 5571406 特許第4033877号公報Japanese Patent No. 40338777 特許第4995155号公報Japanese Patent No. 4995155 特開2016−169199号公報JP-A-2016-169199 特許第4633226号公報Japanese Patent No. 4633226 特開2002−145790号公報JP-A-2002-145790

本発明者らは、コラーゲンペプチドのコラーゲン産生促進機能の増強に注目している。そしてコラーゲンペプチドにバラツボミエキスを併用するとコラーゲンペプチドのコラーゲン産生能が向上することをすでに確認している。
本発明は、コラーゲンペプチドに含有されているトリペプチドであるGly−Pro−Hyp(以下「GPO」)及びGly−Pro−Ala(以下「GPA」)とバラ科バラ属の植物の花弁及び/またはつぼみのエキスを併用すると、極めて強いコラーゲン産生促進作用を発揮することを見出したことからなされたものである。
すなわち、本発明は、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとトリペプチドであるGPO及びGPAを含有する新規な組成物を提供することを課題とする。
The present inventors have focused on enhancing the collagen production promoting function of collagen peptides. It has already been confirmed that the collagen-producing ability of collagen peptide is improved by using rose tsubomi extract in combination with collagen peptide.
The present invention relates to the tripeptides Gly-Pro-Hyp (hereinafter "GPO") and Gly-Pro-Ala (hereinafter "GPA") contained in collagen peptide, and the petals and / or petals of plants belonging to the genus Rosaceae. It was made because it was found that when the bud extract is used in combination, it exerts an extremely strong collagen production promoting effect.
That is, it is an object of the present invention to provide a novel composition containing an extract of petals and / or buds of a plant belonging to the genus Rosa in the family Rosaceae and tripeptides GPO and GPA.

本発明の主な構成は、次のとおりである。
(1) バラ科バラ属の植物の花弁及び/又はつぼみのエキスと、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドを有効成分として含有するコラーゲン産生促進用組成物。
(2)バラ科バラ属の植物の花弁及び/又はつぼみのエキス1質量部あたりGly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドをあわせて1〜200質量部含有する(1)に記載の組成物。
(3)バラ科バラ属の植物が、ガリカローズ、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる1種以上である(1)又は(2)に記載の組成物。
(4)バラ科バラ属の植物の花弁及び/又はつぼみのエキスが水、親水性有機溶媒又はこれらの混合液により抽出処理して得られたエキスである(1)〜(3)のいずれかに記載の組成物。
The main configuration of the present invention is as follows.
(1) A composition for promoting collagen production containing an extract of petals and / or buds of a plant belonging to the genus Rosa in the family Rosaceae and two types of tripeptides having the sequences of Gly-Pro-Hyp and Gly-Pro-Ala as active ingredients. Stuff.
(2) 1 to 200 parts by mass of two types of tripeptides having the sequences of Gly-Pro-Hyp and Gly-Pro-Ala per 1 part by mass of the extract of petals and / or buds of plants of the genus Rosaceae. The composition according to (1).
(3) The composition according to (1) or (2), wherein the plant of the genus Rosa in the family Rosaceae is one or more species selected from Galica rose, dog rose, apotecary rose, sweet briar, damask rose, rose rose and hamanashi. Stuff.
(4) Any of (1) to (3) obtained by extracting the petal and / or bud extract of a plant belonging to the genus Rosa in the family Rosaceae with water, a hydrophilic organic solvent or a mixture thereof. The composition according to.

本発明の組成物は、生体コラーゲン産生を促進する作用を有している。そして本発明の組成物は、バラ科バラ属の植物の花弁及び/又はつぼみのエキスの示すコラーゲン産生促進作用及び、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドの示すコラーゲン産生促進作用が相乗的に作用し、両者の示すコラーゲン産生促進作用をはるかに超えた高いコラーゲン産生促進作用を発揮する。
またバラ科バラ属の植物の花弁及び/又はつぼみのエキスの有する抗菌性や抗ウイルス作用をあわせ持つため、感染症の防御や、感染予後体力回復のための飲食品としても使用可能である。さらにまた、本発明の組成物は、原料とする成分の食経験が長く、安全性が確認されているため、飲食品として経口で摂取することができる。
The composition of the present invention has an action of promoting the production of biological collagen. The composition of the present invention is composed of two types of tripeptides having a collagen production promoting action exhibited by an extract of petals and / or buds of a plant belonging to the genus Rosaceae, and a sequence of Gly-Pro-Hyp and Gly-Pro-Ala. The collagen production promoting action shown in the above acts synergistically, and exerts a high collagen production promoting action far exceeding the collagen production promoting action shown by both.
In addition, since it also has antibacterial and antiviral effects of the petals and / or bud extracts of plants belonging to the genus Rosaceae, it can be used as a food or drink for protection against infectious diseases and recovery of prognosis and physical strength. Furthermore, the composition of the present invention can be orally ingested as a food or drink because the ingredients used as raw materials have a long eating experience and their safety has been confirmed.

バラつぼみエキスとGly−Pro−Hyp(GPO)、Gly−Pro−Ala(GPA)1:1混合物によるI型コラーゲン産生促進試験の結果を示すグラフである。It is a graph which shows the result of the type I collagen production promotion test by the rose bud extract, Gly-Pro-Hyp (GPO), Gly-Pro-Ala (GPA) 1: 1 mixture. バラつぼみエキスGly−Pro−Hyp(GPO)、Gly−Pro−Ala(GPA)2:1混合物によるI型コラーゲン産生促進試験の結果を示すグラフである。It is a graph which shows the result of the type I collagen production promotion test by the rose bud extract Gly-Pro-Hyp (GPO), Gly-Pro-Ala (GPA) 2: 1 mixture.

本発明は、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとトリペプチドを含有するコラーゲン産生促進用組成物に関する。
本発明の組成物について説明する。
バラ科バラ属の植物の花弁及び/又はつぼみは、どのような品種から採取したものでもかまわないが、園芸種として大量に栽培されているものが産業上好ましい。このようなものとして特にガリカローズ(Rosa gallica)、ドッグローズ(Rosa canina)、アポテカリーズローズ(Rosa gallica officinalis)、スイートブライヤー(Rosa rubiginosa)、ダマスクバラ(Rosa damascena trigintipetala)、セイヨウバラ(Rosa centifolia)及びハマナシ(Rosa rugosarubra)が好ましい。
The present invention relates to a collagen production promoting composition containing an extract of petals and / or buds of a plant belonging to the genus Rosaceae and a tripeptide.
The composition of the present invention will be described.
The petals and / or buds of plants belonging to the genus Rosa in the Rosaceae family may be collected from any variety, but those cultivated in large quantities as horticultural species are industrially preferable. These include, in particular, Rosa gallica, dog rose (Rosa canina), apotecalis rose (Rosa gallica officinalis), sweet briginosa, damask rose (Rosa dasai rose), damask rose (Rosa dasai). And hamanashi (Rosa rugosarubra) are preferred.

例えば、バラ科バラ属の植物の花弁又はつぼみを生のまま又は乾燥した後、そのまま又は粗砕機を用い粉砕して溶媒抽出に供することにより得ることができる。抽出に用いる溶媒としては、水又は親水性有機溶媒及びこれらの混合液を室温乃至溶媒の沸点以下の温度で用いることが好ましい。具体的には、メタノール、エタノール等の低級アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール等の炭素数2〜4の多価アルコール、及びこれら親水性有機溶媒と水との混合溶媒などを用いることができる。なお、水と親水性有機溶媒との混合系溶媒を使用する場合には、低級アルコールの場合は水10質量部に対して1〜90質量部、低級脂肪族ケトンの場合は水10質量部に対して1〜40質量部、多価アルコールの場合は水10質量部に対して10〜90質量部添加することが好ましい。 For example, it can be obtained by raw or drying the petals or buds of a plant belonging to the genus Rosa in the family Rosaceae, and then pulverizing the plants as they are or using a coarse crusher for solvent extraction. As the solvent used for extraction, it is preferable to use water or a hydrophilic organic solvent and a mixed solution thereof at a temperature of room temperature to a temperature equal to or lower than the boiling point of the solvent. Specifically, lower alcohols such as methanol and ethanol; lower aliphatic ketones such as acetone and methyl ethyl ketone; polyhydric alcohols having 2 to 4 carbon atoms such as 1,3-butylene glycol and propylene glycol, and these hydrophilic organic solvents. A mixed solvent of water and water can be used. When a mixed solvent of water and a hydrophilic organic solvent is used, the amount of lower alcohol is 1 to 90 parts by mass with respect to 10 parts by mass of water, and the amount of lower aliphatic ketone is 10 parts by mass of water. On the other hand, it is preferable to add 1 to 40 parts by mass, and in the case of polyhydric alcohol, 10 to 90 parts by mass with respect to 10 parts by mass of water.

この場合、抽出処理は、室温乃至還流加熱下で、任意の装置を用いて行うことができる。例えば、抽出溶媒を満たした処理槽にバラ科バラ属の植物のつぼみ(又は花弁)を投入し、必要に応じて時々攪拌しながら、30分〜2時間静置して可溶性成分を溶出した後、濾過して固形物を除去し、得られた抽出液から抽出溶媒を溜去し、乾燥することにより赤褐色のバラエキスが得られる。抽出条件は、抽出溶媒として水を用いた場合には、通常50〜90℃で30分〜2時間程度である。また、抽出溶媒として水とエタノールとの混合溶媒を用いた場合には、通常40〜80℃で30分〜2時間程度である。なお、溶媒で抽出することにより得られる抽出液は、抽出溶媒が安全性の高いものであればそのまま配合して本発明の有効成分として用いることができる。特許文献6には具体的な製造方法が開示されており、これにしたがって本発明に適したエキスを得ることができる。 In this case, the extraction process can be carried out at room temperature or under reflux heating using any device. For example, the buds (or petals) of plants belonging to the genus Rosaceae are put into a treatment tank filled with an extraction solvent, and the soluble components are eluted by allowing them to stand for 30 minutes to 2 hours with occasional stirring as needed. , The solid matter is removed by filtration, the extraction solvent is distilled off from the obtained extract, and the extract is dried to obtain a reddish brown rose extract. When water is used as the extraction solvent, the extraction conditions are usually about 30 minutes to 2 hours at 50 to 90 ° C. When a mixed solvent of water and ethanol is used as the extraction solvent, it is usually about 30 minutes to 2 hours at 40 to 80 ° C. The extract obtained by extracting with a solvent can be used as an active ingredient of the present invention by blending it as it is as long as the extraction solvent has high safety. Patent Document 6 discloses a specific production method, and an extract suitable for the present invention can be obtained according to this.

このようにして得られるバラ科バラ属の植物のエキスは、原料に由来する好ましい風味を有しており、そのまま本発明に利用可能であるが、必要に応じて、脱色等を目的とする精製を施し、配合用途に応じて、アルコールその他の有機溶剤の溶液又は水溶液の形として利用することができる。 The extract of the Rosaceae plant of the Rosaceae family thus obtained has a preferable flavor derived from the raw material and can be used as it is in the present invention, but if necessary, it is purified for the purpose of decolorization or the like. It can be used as a solution of alcohol or other organic solvent or in the form of an aqueous solution, depending on the compounding application.

本発明に用いるバラ科バラ属の植物のエキスは、必要によりデキストリンやシクロデキストリンを添加して、噴霧乾燥などの乾燥手段で粉末化することもできる。
本発明に用いるバラ科バラ属の植物のエキスは、市販されているものを使用することができる。本発明に適した、バラのつぼみのエキスの噴霧乾燥品である丸善製薬株式会社製の「ローズバッツエキスパウダーMF」を例示できる。
本発明に用いるバラ科バラ属の植物エキスは、ポリフェノールとして5質量%以上含有し、好ましくは10〜80質量%、特に好ましくは10〜20質量%含有するものである。
なお、本発明に用いるバラ科バラ属の植物のエキス量は、植物抽出物由来の固形分相当量を指す。
The extract of a plant belonging to the genus Rosaceae used in the present invention can be pulverized by a drying means such as spray drying by adding dextrin or cyclodextrin, if necessary.
As the extract of the plant of the genus Rosa in the family Rosaceae used in the present invention, a commercially available extract can be used. An example is “Rose Butts Extract Powder MF” manufactured by Maruzen Pharmaceuticals Co., Ltd., which is a spray-dried rose bud extract suitable for the present invention.
The plant extract of the genus Rosaceae used in the present invention contains 5% by mass or more of polyphenol, preferably 10 to 80% by mass, and particularly preferably 10 to 20% by mass.
The amount of the extract of a plant belonging to the genus Rosaceae used in the present invention refers to the amount equivalent to the solid content derived from the plant extract.

本発明に用いるトリペプチドは、コラーゲンの酵素加水分解によって得られるコラーゲンペプチド中に含有されているトリペプチドが好ましく、豚、ウシなどの動物由来、魚由来のいずれも使用可能である。また、合成品であっても良い。
本発明のトリペプチドのアミノ酸配列は、Gly−Pro−Hyp及びGly−Pro−Alaの両成分を含有する。
また、GPO:GPAの比率が1:1〜3:1であるものが好ましいがこの限りではない。
The tripeptide used in the present invention is preferably a tripeptide contained in a collagen peptide obtained by enzymatic hydrolysis of collagen, and any animal-derived tripeptide such as pig or cow, or fish-derived tripeptide can be used. Moreover, it may be a synthetic product.
The amino acid sequence of the tripeptide of the present invention contains both Gly-Pro-Hyp and Gly-Pro-Ala components.
Further, it is preferable that the ratio of GPO: GPA is 1: 1 to 1-3: 1, but this is not the case.

本発明にあっては、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとトリペプチドの相乗作用によってコラーゲン産生を促進する。このような相乗効果を得るためには、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとコラーゲントリペプチド(GPO及びGPAの合計)の配合比は、バラ科バラ属の植物の花弁及び/又はつぼみのエキス1質量部に対し1〜300質量部、好ましくは1〜200質量部、特に好ましくは5〜150質量部を含有する組成物とする。 In the present invention, collagen production is promoted by the synergistic action of the petal and / or bud extract of a plant belonging to the genus Rosa in the family Rosaceae and a tripeptide. In order to obtain such a synergistic effect, the blending ratio of the petal and / or bud extract of the Rosaceae plant and the collagen tripeptide (total of GPO and GPA) should be adjusted to the petals and / or bud plant petals and / Or a composition containing 1 to 300 parts by mass, preferably 1 to 200 parts by mass, and particularly preferably 5 to 150 parts by mass with respect to 1 part by mass of the bud extract.

この組成物を飲食品に添加する場合、 添加量は、0.01質量%以上、好ましくは0.5〜95質量%、特に好ましくは5〜90質量%である。医薬品とする場合、症状及び対象とする年齢や、体重、投与する剤形によって異なるため一義的に配合量を決定できない。 When this composition is added to foods and drinks, the amount added is 0.01% by mass or more, preferably 0.5 to 95% by mass, and particularly preferably 5 to 90% by mass. In the case of a drug, the amount to be blended cannot be uniquely determined because it depends on the symptom, the target age, the body weight, and the dosage form to be administered.

食品としては、通常の食品の他、栄養補助食品、機能性食品、健康食品、特定保健用食品等として、例えば、錠剤、カプセル、パウダー等のような形態が好ましい。その他、ジュースのような飲料、ゼリーに配合することもできる。 As the food, in addition to ordinary foods, nutritional supplements, functional foods, health foods, foods for specified health uses and the like, for example, tablets, capsules, powders and the like are preferable. In addition, it can be added to beverages such as juice and jelly.

医薬品用途において、投与に関しては、有効成分を経口投与、非経口摂取の場合、直腸内投与、注射等の投与方法に適した固体又は液体の医薬用無毒性担体と混合して、慣用の医薬製剤の形態で投与することができる。形態としては、例えば、粉末、散剤、顆粒、錠剤、カプセル等の固形剤、溶液剤、懸濁剤、乳剤等の液剤、凍結乾燥製剤等が挙げられる。これらの製剤は常套手段により調製することが可能である。上記の医薬品用担体としては、例えば、グルコース、乳糖、ショ糖、澱粉、マンニトール、デキストリン、脂肪酸グリセリド、ポリエチレングリコール、ヒドロキシエチレンデンプン、エチレングリコール、ポリオキシエチレンソルビタン脂肪酸エステル、アミノ酸、ゼラチン、アルブミン、水、生理食塩水等が挙げられる。必要に応じて、安定化剤、湿潤剤、乳化剤、結合剤、等張化剤等の添加剤を適宜添加することも可能である。 In pharmaceutical applications, the active ingredient is mixed with a solid or liquid medicinal non-toxic carrier suitable for administration methods such as rectal administration and injection in the case of oral administration or parenteral ingestion, and is used as a conventional pharmaceutical preparation. Can be administered in the form of. Examples of the form include solid preparations such as powders, powders, granules, tablets and capsules, liquid preparations such as solutions, suspensions and emulsions, and freeze-dried preparations. These formulations can be prepared by conventional means. Examples of the above-mentioned pharmaceutical carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethylene starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin, and water. , Physiological saline and the like. If necessary, additives such as stabilizers, wetting agents, emulsifiers, binders and isotonic agents can be added as appropriate.

以下に本発明の組成物を用いたコラーゲン産生促進試験例及び比較試験例を示し、 本発明を具体的に説明する。
<1.トリペプチドGPO及びGPAの1:1混合物とバラつぼみエキスの併用効果確認試験>
(1)試験試料(サンプル)
バラ科バラ属の植物の花弁及び/又はつぼみのエキスとして、丸善製薬株式会社が販売
しているローズバッツエキスパウダーMFを用いた。またトリペプチドとして、Gly−Pro−Hyp(GPO)配列表配列番号1及びGly−Pro−Ala(GPA)配列表配列番号2を用いた。GPO、GPAは化学合成品の試薬純度のものを用いた。
Hereinafter, the present invention will be specifically described with reference to Examples of Collagen Production Promotion Test Examples and Comparative Test Examples Using the Composition of the Present Invention.
<1. Test to confirm the combined effect of a 1: 1 mixture of tripeptide GPO and GPA and rose bud extract>
(1) Test sample (sample)
Rose Butts Extract Powder MF sold by Maruzen Pharmaceuticals Co., Ltd. was used as an extract of petals and / or buds of plants belonging to the genus Rosa in the family Rosaceae. Further, as the tripeptide, Gly-Pro-Hyp (GPO) SEQ ID NO: 1 and Gly-Pro-Ala (GPA) SEQ ID NO: 2 were used. As GPO and GPA, those having reagent purity of chemically synthesized products were used.

(2)試験方法
1)使用細胞
正常ヒト皮膚線維芽細胞(NHDF:ロンザジャパン株式会社)
(2) Test method 1) Cells used Normal human skin fibroblasts (NHDF: Lonza Japan Co., Ltd.)

2)細胞培養
細胞は37℃、5%二酸化炭素、95%空気の条件下で培養を行った。培地は非働化したウシ胎児血清(FBS)(Hyclone laboratories)10%、penicilin−Streptmycin(Sigma Aldrich)1%を添加したダルベッコ改変イーグル培地(高グルコース含有、life technologies)を用いた。以降、この培地を「基礎培地」と表記する。通常培養には10cmまたは15cmディッシュを用い、継代時の細胞剥離には0.05%Trypsin−EDTA(Sigma Aldrich)を使用した。
2) Cell culture The cells were cultured under the conditions of 37 ° C., 5% carbon dioxide and 95% air. As the medium, Dulbecco's modified Eagle's medium (high glucose content, life technologies) supplemented with 10% of deactivated fetal bovine serum (FBS) (Hyclone laboratories) and 1% of penicillin-Streptomycin (Sigma-Aldrich) was used. Hereinafter, this medium will be referred to as "basal medium". A 10 cm or 15 cm dish was used for normal culture, and 0.05% Trypsin-EDTA (Sigma Aldrich) was used for cell detachment during passage.

(3)試験試料調製
試験試料は培地で溶解した。UVA照射前は基礎培地を用い、UVA照射後はFBS不含基礎培地を用いた。
試験試料の最終濃度
下記表1の濃度で試験を実施した。
(3) Preparation of test sample The test sample was dissolved in the medium. A basal medium was used before UVA irradiation, and an FBS-free basal medium was used after UVA irradiation.
Final Concentration of Test Sample The test was carried out at the concentration shown in Table 1 below.

(4)細胞の形態観察
添加による影響を確認するため形態観察を行った。形態観察には倒立型システム顕微鏡(OLYMPUS IX70)を用いて行った。
(4) Cell morphology observation A morphology observation was performed to confirm the effect of the addition. The morphology was observed using an inverted system microscope (OLYMPUS IX70).

(5)コラーゲン産生量の確認試験
24wellプレートに細胞を1×10cells/500μL/wellで播種した。1日前培養した後、評価試料を含む基礎培地500μLと交換して1日培養した。その後、ハンクス平衡塩溶液(HBSS、カルシウム・マグネシウム含有、フェノールレッド不含)500μLに置換し、蓋を取ったディッシュをUVA照射ランプの下に一列に置いて12J/cm照射した(約132分)。照射後、HBSSを取り除き、サンプル入りのFBS不含基礎培地500μLと交換して2日間培養した。培地を回収し、−80℃中に保存した。培地回収後、ディッシュを500μLのリン酸緩衝生理食塩水で3回洗浄し、0.1Nの水酸化ナトリウム溶液200μLで懸濁し、細胞を回収した。
回収した培地は4℃、10,000×gで10分間遠心し、その上清中のI型コラーゲン量をCollagen Type I, Human, ELISA Kit(株式会社エーセル)を用いて測定した。細胞懸濁液は4℃、10,000×gで10分間遠心し、その上清中のタンパク量をPierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC)を用いて測定した。培地中のI型コラーゲン量は細胞タンパク量で補正した。また測定結果はコントロール(無添加)細胞のコラーゲン産生量に対する増加量を求め、増加率%を得た。なお結果は、3回試験した結果のコラーゲン産生増加率の平均値で示す。
(5) Confirmation test of collagen production The cells were seeded on a 24-well plate at 1 × 10 5 cells / 500 μL / well. After culturing one day before, the cells were replaced with 500 μL of the basal medium containing the evaluation sample and cultured for one day. Then, it was replaced with 500 μL of Hanks balanced salt solution (HBSS, calcium / magnesium-containing, phenol red-free), and the dishes with the lid removed were placed in a row under the UVA irradiation lamp and irradiated with 12 J / cm 2 (about 132 minutes). ). After irradiation, HBSS was removed, replaced with 500 μL of FBS-free basal medium containing a sample, and cultured for 2 days. Medium was collected and stored at -80 ° C. After collecting the medium, the dish was washed 3 times with 500 μL of phosphate buffered saline, suspended in 200 μL of 0.1 N sodium hydroxide solution, and the cells were recovered.
The collected medium was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of type I collagen in the supernatant was measured using Collagen Type I, Human, and ELISA Kit (Acel Co., Ltd.). The cell suspension was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of protein in the supernatant was measured using a Pierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC). The amount of type I collagen in the medium was corrected by the amount of cellular protein. As for the measurement result, the amount of increase with respect to the amount of collagen produced by the control (additive-free) cells was obtained, and the rate of increase was obtained. The results are shown by the average value of the collagen production increase rate as a result of the three tests.

(6)試験結果
試験結果を表1及び図1に示す。
(6) Test results The test results are shown in Table 1 and FIG.

表1及び図1から、バラつぼみエキスとGPOとGPA1:1混合トリペプチドの併用は顕著にコラーゲン産生を促進することが明らかとなった。 From Table 1 and FIG. 1, it was clarified that the combined use of rose bud extract, GPO and GPA 1: 1 mixed tripeptide significantly promotes collagen production.

またGPOとGPA1:1混合トリペプチドとバラつぼみエキス併用によるI型コラーゲン産生相乗効果の評価は、以下の基準で判定した。

相乗効果有りの評価:相加効果の理論値<実測値の場合を相乗効果「有」として判定した。
相加効果の理論値=(A/D−1)×100+(B/D−1)×100
実測値=(C/D−1)×100

A:バラつぼみエキス単独添加によるI型コラーゲン産生量
B:トリペプチド混合物添加によるI型コラーゲン産生量
C:バラつぼみエキスとトリペプチド混合物の併用によるI型コラーゲン産生量
D:コントロール群(無添加サンプル)のI型コラーゲン産生量
併用効果の判定表を、下記の表2に示す。
The evaluation of the synergistic effect of type I collagen production by the combined use of GPO and GPA 1: 1 mixed tripeptide and rose bud extract was judged according to the following criteria.

Evaluation of synergistic effect: The case where the theoretical value of the additive effect <the measured value was judged as having the synergistic effect.
Theoretical value of additive effect = (A / D-1) x 100 + (B / D-1) x 100
Measured value = (C / D-1) x 100

A: Type I collagen production by adding rose bud extract alone B: Type I collagen production by adding tripeptide mixture C: Type I collagen production by using rose bud extract and tripeptide mixture together D: Control group (sample without addition) ) I type collagen production amount The judgment table of the combined effect is shown in Table 2 below.

バラつぼみエキスとトリペプチドGPO、GPA混合物の併用により、I型コラーゲンの産生量が相乗的に上昇したことが確認できた。 It was confirmed that the combined use of the rose bud extract, the tripeptide GPO, and the GPA mixture synergistically increased the amount of type I collagen produced.

<2.トリペプチドGPO及びGPAの2:1混合物とバラつぼみエキスの併用効果確認試験>
(1)試験試料(サンプル)
バラ科バラ属の植物の花弁及び/又はつぼみのエキスとして、丸善製薬株式会社が販売
しているローズバッツエキスパウダーMFを用いた。またトリペプチドとして、試験1と同様にGPOとGPAを用いた。
<2. Test to confirm the combined effect of a 2: 1 mixture of tripeptide GPO and GPA and rose bud extract>
(1) Test sample (sample)
Rose Butts Extract Powder MF sold by Maruzen Pharmaceuticals Co., Ltd. was used as an extract of petals and / or buds of plants belonging to the genus Rosa in the family Rosaceae. As the tripeptide, GPO and GPA were used as in Test 1.

(2)試験方法
1)使用細胞
正常ヒト皮膚線維芽細胞(NHDF:ロンザジャパン株式会社)
(2) Test method 1) Cells used Normal human skin fibroblasts (NHDF: Lonza Japan Co., Ltd.)

2)細胞培養
細胞は37℃、5%二酸化炭素、95%空気の条件下で培養を行った。培地は非働化したウシ胎児血清(FBS)(Hyclone laboratories)10%、penicilin−Streptmycin(Sigma Aldrich)1%を添加したダルベッコ改変イーグル培地(高グルコース含有、life technologies)を用いた。通常培養には10cmまたは15cmディッシュを用い、継代時の細胞剥離には0.05%Trypsin−EDTA(Sigma Aldrich)を使用した。
2) Cell culture The cells were cultured under the conditions of 37 ° C., 5% carbon dioxide and 95% air. As the medium, Dulbecco's modified Eagle's medium (high glucose content, life technologies) supplemented with 10% of deactivated fetal bovine serum (FBS) (Hyclone laboratories) and 1% of penicillin-Streptomycin (Sigma-Aldrich) was used. A 10 cm or 15 cm dish was used for normal culture, and 0.05% Trypsin-EDTA (Sigma Aldrich) was used for cell detachment during passage.

(3)試験試料調製
試験試料は培地で溶解した。UVA照射前は基礎培地を用い、UVA照射後はFBS
不含基礎培地を用いた。
試験試料の最終濃度
下記表3の濃度で試験を実施した。
(3) Preparation of test sample The test sample was dissolved in the medium. Use basal medium before UVA irradiation and FBS after UVA irradiation
A basal-free medium was used.
Final Concentration of Test Sample The test was carried out at the concentrations shown in Table 3 below.

(4)細胞の形態観察
添加による影響を確認するため形態観察を行った。形態観察には倒立型システム顕微鏡(OLYMPUS IX70)を用いて行った。
(4) Cell morphology observation A morphology observation was performed to confirm the effect of the addition. The morphology was observed using an inverted system microscope (OLYMPUS IX70).

(5)コラーゲン産生量の確認試験
24wellプレートに細胞を1×10cells/500μL/wellで播種した。1日前培養した後、サンプル入り基礎培地500μLと交換して1日培養した。その後、ハンクス平衡塩溶液(HBSS、カルシウム・マグネシウム含有、フェノールレッド不含)500μLに置換し、蓋を取ったディッシュをUVA照射ランプの下に一列に置いて12J/cm照射した(約132分)。照射後、HBSSを取り除き、サンプル入りのFBS不含基礎培地500μLと交換して2日間培養した。培地を回収し、−80℃中に保存した。培地回収後、ディッシュを500μLのリン酸緩衝生理食塩水で3回洗浄し、0.1Nの水酸化ナトリウム溶液200μLで懸濁し、細胞を回収した。
(5) Confirmation test of collagen production The cells were seeded on a 24-well plate at 1 × 10 5 cells / 500 μL / well. After culturing one day before, the cells were replaced with 500 μL of basal medium containing a sample and cultured for one day. Then, it was replaced with 500 μL of Hanks balanced salt solution (HBSS, calcium / magnesium-containing, phenol red-free), and the dishes with the lid removed were placed in a row under the UVA irradiation lamp and irradiated with 12 J / cm 2 (about 132 minutes). ). After irradiation, HBSS was removed, replaced with 500 μL of FBS-free basal medium containing a sample, and cultured for 2 days. Medium was collected and stored at -80 ° C. After collecting the medium, the dish was washed 3 times with 500 μL of phosphate buffered saline, suspended in 200 μL of 0.1 N sodium hydroxide solution, and the cells were recovered.

回収した培地は4℃、10,000×gで10分間遠心し、その上清中のI型コラーゲン量をCollagen Type I, Human, ELISA Kit(株式会社エーセル)を用いて測定した。細胞懸濁液は4℃、10,000×gで10分間遠心し、その上清中のタンパク量をPierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC)を用いて測定した。培地中のI型コラーゲン量は細胞タンパク量で補正した。また測定結果はコントロール(無添加)細胞のコラーゲン産生量に対する増加量を求め、増加率%を得た。なお結果は、3回試験した結果のコラーゲン産生増加率の平均値で示す。 The collected medium was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of type I collagen in the supernatant was measured using Collagen Type I, Human, and ELISA Kit (Acel Co., Ltd.). The cell suspension was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of protein in the supernatant was measured using a Pierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC). The amount of type I collagen in the medium was corrected by the amount of cellular protein. As for the measurement result, the amount of increase with respect to the amount of collagen produced by the control (additive-free) cells was obtained, and the rate of increase was obtained. The results are shown by the average value of the collagen production increase rate as a result of the three tests.

(6)試験結果
試験結果を表3及び図2に示す。
(6) Test results The test results are shown in Table 3 and FIG.

表3及び図2から、バラつぼみエキスとGPOとGPA2:1混合トリペプチドの併用は、コラーゲン産生を促進することが明らかとなった。 From Table 3 and FIG. 2, it was clarified that the combined use of rose bud extract, GPO and GPA 2: 1 mixed tripeptide promotes collagen production.

またGPOとGPA2:1混合トリペプチドとバラつぼみエキス併用によるI型コラーゲン産生相乗効果の評価は、以下の基準で判定した。

相乗効果有りの評価:相加効果の理論値<実測値の場合を相乗効果「有」として判定した。
相加効果の理論値=(A/D−1)×100+(B/D−1)×100
実測値=(C/D−1)×100

A:バラつぼみエキス単独添加によるI型コラーゲン産生量
B:トリペプチド混合物添加によるI型コラーゲン産生量
C:バラつぼみエキスとトリペプチド混合物の併用によるI型コラーゲン産生量
D:コントロール群(無添加サンプル)のI型コラーゲン産生量
併用効果の判定表を、下記の表4に示す。
The evaluation of the synergistic effect of type I collagen production by the combined use of GPO and GPA 2: 1 mixed tripeptide and rose bud extract was judged according to the following criteria.

Evaluation of synergistic effect: The case where the theoretical value of the additive effect <the measured value was judged as having the synergistic effect.
Theoretical value of additive effect = (A / D-1) x 100 + (B / D-1) x 100
Measured value = (C / D-1) x 100

A: Type I collagen production by adding rose bud extract alone B: Type I collagen production by adding tripeptide mixture C: Type I collagen production by using rose bud extract and tripeptide mixture together D: Control group (sample without addition) ) I type collagen production amount The judgment table of the combined effect is shown in Table 4 below.

バラつぼみエキスとトリペプチドGPO、GPA混合物の併用により、I型コラーゲンの産生量が相乗的に上昇したことが確認できた。 It was confirmed that the combined use of the rose bud extract, the tripeptide GPO, and the GPA mixture synergistically increased the amount of type I collagen produced.

<3.試験結果まとめ>
以上の試験1及び2から次の点が明らかとなった。
(1)バラつぼみエキスとGPO、GPAの混合物を併用すると生体のコラーゲン産生が相乗的に促進される。
(2)トリペプチドGPOとGPAの配合比率は、GPO:GPAの比率が1:1又は2:1の比率になるように混合して試験したが、いずれの場合もバラつぼみエキスと併用することでコラーゲン産生が相乗的に増加した。
<3. Test result summary>
The following points were clarified from the above tests 1 and 2.
(1) When a mixture of rose bud extract and GPO and GPA is used in combination, collagen production in a living body is synergistically promoted.
(2) The mixing ratio of tripeptide GPO and GPA was mixed and tested so that the ratio of GPO: GPA was 1: 1 or 2: 1. In either case, it should be used in combination with the rose bud extract. Collagen production increased synergistically.

参考製造例1
バラ科バラ属の植物のつぼみのエキスの製造例
アポテカリーズローズのつぼみ(Rosa gallica officinalis)300gに50質量%エタノールを2000mL加え、還流冷却器を付けて、80℃にて1時間抽出した後、濾紙で濾過して抽出液1を得た。また、抽出残渣に50重量%エタノール1500mLを加え、同様に還流冷却器を付けて、80℃にて1時間抽出した後、濾紙で濾過して抽出液2を得た。得られた抽出液1、2を合せて減圧下で濃縮、乾燥させて粉末エキス100gを得た(収率33.3%)。
Reference manufacturing example 1
Example of production of bud extract of a plant belonging to the genus Rosa of the Rosaceae family Add 2000 mL of 50% by mass ethanol to 300 g of buds (Rosa gallica officinalis), attach a reflux cooler, and extract at 80 ° C. for 1 hour. , The extract 1 was obtained by filtering with a filter paper. Further, 1500 mL of 50 wt% ethanol was added to the extraction residue, and the mixture was similarly attached with a reflux condenser, extracted at 80 ° C. for 1 hour, and then filtered through a filter paper to obtain an extract 2. The obtained extracts 1 and 2 were combined, concentrated under reduced pressure, and dried to obtain 100 g of a powder extract (yield 33.3%).

参考製造例2
バラ科バラ属の植物のつぼみのエキスの製造例
セイヨウバラのつぼみ(Rosa centifolia)300gに水2000mLを加え、90℃にて1時間抽出を行った後、濾紙にて濾過し、抽出液を得た。得られた抽出液を減圧下で濃縮、乾燥させて、製造例2の粉末エキス100gを得た(収率33.3%)。
Reference manufacturing example 2
Example of production of extract of buds of plants belonging to the genus Rosa in the family Rosaceae Add 2000 mL of water to 300 g of buds of roses (Rosa centifolia), extract at 90 ° C. for 1 hour, and then filter with filter paper to obtain an extract. It was. The obtained extract was concentrated under reduced pressure and dried to obtain 100 g of the powder extract of Production Example 2 (yield 33.3%).

Claims (2)

バラ科バラ属の植物の花弁及び/又はつぼみのエキスと、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドを有効成分として含有するコラーゲン産生促進用組成物であって、
バラ科バラ属の植物の花弁及び/又はつぼみのエキス1質量部あたりGly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドをあわせて1〜200質量部含有するコラーゲン産生促進用組成物
And it rose species petals and / or buds of the plant extracts, met Gly-Pro-Hyp and Gly-Pro-Ala 2 types of collagen production promoting composition containing tripeptide as an active ingredient having the sequence of hand,
Collagen production containing 1 to 200 parts by mass of two types of tripeptides having the sequences of Gly-Pro-Hyp and Gly-Pro-Ala per 1 part by mass of the extract of petals and / or buds of plants of the genus Rosaceae. Acceleration composition .
バラ科バラ属の植物が、ガリカローズ、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる1種以上である請求項1に記載の組成物。 The composition according to claim 1, wherein the plant of the genus Rosa in the family Rosaceae is at least one selected from Galica rose, dog rose, apotecary rose, sweet-brier, damask rose, rose rose and hamanashi.
JP2019125060A 2019-07-04 2019-07-04 Composition for promoting collagen production Active JP6777794B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2019125060A JP6777794B1 (en) 2019-07-04 2019-07-04 Composition for promoting collagen production
CN202010619260.2A CN112167634B (en) 2019-07-04 2020-07-01 Composition for promoting collagen production
TW109122398A TWI855104B (en) 2019-07-04 2020-07-02 Composition for acceleration of collagen production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019125060A JP6777794B1 (en) 2019-07-04 2019-07-04 Composition for promoting collagen production

Publications (2)

Publication Number Publication Date
JP6777794B1 true JP6777794B1 (en) 2020-10-28
JP2021011439A JP2021011439A (en) 2021-02-04

Family

ID=72938129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019125060A Active JP6777794B1 (en) 2019-07-04 2019-07-04 Composition for promoting collagen production

Country Status (2)

Country Link
JP (1) JP6777794B1 (en)
CN (1) CN112167634B (en)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768621B1 (en) * 1997-09-22 2000-04-07 Oreal USE OF AN EXTRACT OF AT LEAST ONE PLANT FROM THE ROSACEA FAMILY
JP2003137807A (en) * 2001-11-01 2003-05-14 Miyagi Kagaku Kogyo Kk Collagen-producing promoter, cosmetic, food and pharmaceutical containing the same and external preparation for preventing or improving dermatosis
JP2003176219A (en) * 2001-12-13 2003-06-24 Ichimaru Pharcos Co Ltd Collagen tripeptide-containing skin care preparation
JP2003300818A (en) * 2002-04-11 2003-10-21 Harada:Kk Cosmetic
JP2004067552A (en) * 2002-08-05 2004-03-04 Naris Cosmetics Co Ltd Collagen production promoter, and cosmetic containing the same
JP4286513B2 (en) * 2002-09-26 2009-07-01 株式会社ファンケル Anti-aging composition
JP4033877B2 (en) * 2005-09-29 2008-01-16 株式会社ファンケル Composition for promoting type I collagen production
DE102009030351A1 (en) * 2009-06-22 2010-12-23 Gelita Ag Composition for the treatment of degenerative joint diseases
JP2011236156A (en) * 2010-05-11 2011-11-24 Pola Chemical Industries Inc Collagen production promoter
JP2012153614A (en) * 2011-01-24 2012-08-16 Unitika Ltd Collagen production promoter
WO2014062607A1 (en) * 2012-10-15 2014-04-24 Commercial Marine Biology Institute, Llc Marine extract compositions and methods of use
JP6448216B2 (en) * 2014-05-02 2019-01-09 株式会社ニッピ Method for preparing peptide composition, cell culture method, and peptide composition
EP3146957A4 (en) * 2014-05-19 2017-11-15 Suntory Holdings Limited Novel use of rose dye compound
JP2016044150A (en) * 2014-08-25 2016-04-04 富士フイルム株式会社 Cosmetic
CN105919836A (en) * 2016-04-21 2016-09-07 珠海安和生化科技有限公司 Anti-wrinkle composition added with plant essential oil and bioactive polypeptide and preparation method of anti-wrinkle composition
CN107397716A (en) * 2017-08-09 2017-11-28 陕西沐千惠商贸有限公司 Promote cell turnover and can compact fair-skinned white product and preparation method

Also Published As

Publication number Publication date
JP2021011439A (en) 2021-02-04
CN112167634A (en) 2021-01-05
CN112167634B (en) 2024-03-01
TW202116346A (en) 2021-05-01

Similar Documents

Publication Publication Date Title
TWI594766B (en) Collagen production promoter, hyaluronic acid production promoter, fibroblast proliferation promoter and anti-wrinkle agent
JP6606378B2 (en) Collagen production promoter
WO2007148739A1 (en) Cell activator, anti-aging agent and extracellular matrix production promoter derived from plant
JP4826696B2 (en) Angiogenesis inhibitors
JP2010155820A (en) Skin ameliorating agent, and vascular ameliorating agent, and pharmaceutical composition, food, feed and cosmetic comprising the same
JP2009067749A (en) Matrix metalloprotease-1(mmp-1) inhibitor, matrix metalloprotease-2(mmp-2) inhibitor, estrogen-like action agent, profilaggrin production promoter, filaggrin production promoter, antiobese agent and cyclic amp phosphodiesterase activity inhibitor
KR101449763B1 (en) Phaseolus vulgaris extracts, their use, and formulations containing them
JP5459826B2 (en) Elastin production promoter and vascular endothelial cell growth promoter in dermal fibroblasts
JP6807535B2 (en) Fibroblast growth factor
KR102511701B1 (en) Functional collagen composition using collagen amino acid derived from Aurea Helianthus
JP6777794B1 (en) Composition for promoting collagen production
JP6517546B2 (en) Fibroblast cell proliferation promoter
JP2016056116A (en) Composition for promoting collagen production
CN111466576A (en) Food additive
JP6553790B1 (en) Composition for promoting collagen production
JP2011225495A (en) Vascular endothelial cell protecting agent, and pharmaceutical composition, food and feed containing the same
TWI855104B (en) Composition for acceleration of collagen production
JP2003246741A (en) Oral skin improver, food composition for skin improvement and skin improvement process
KR20200079215A (en) Composition for Silkworm-collagen and manufacturing method thereof
JP6143218B2 (en) Tendon and ligament function improving agent and pharmaceutical composition, food and feed containing the same
KR101839582B1 (en) Composition for activating cell comprising bran extracts and Method of cell activation
JP6619530B2 (en) Composition for inhibiting matrix metalloprotease production
KR101491902B1 (en) Novel Peptide with collagenase inhibitory activity and use thereof
JP2019140996A (en) Collagen production promoting agent
JP5063040B2 (en) Angiogenesis inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200318

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200318

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200707

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201008

R150 Certificate of patent or registration of utility model

Ref document number: 6777794

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250